Transfer of a mutated gene encoding active transforming growth factor-β1 suppresses mitogenesis and IL-1 response in the glomerulus  by Kitamura, Masanori et al.
Kidney International, Vol. 48 (1995), pp. 1 74 7—1 757
Transfer of a mutated gene encoding active transforming
growth factor-f31 suppresses mitogenesis and IL-i response
in the glomerulus
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Transfer of a mutated gene encoding active transforming growth
factor43l suppresses mitogenesis and IL-i response in the glomerulus.
Using in vivo gene transfer, we examined the anti-inflammatory potential
of transforming growth factor-/il (TGF-131) in the renal glomerulus.
TGF-131 eDNA, modified to allow for secretion of the active form of
TGF-/31, was introduced into cultured rat mesangial cells. The responses
of the established transfectants were examined in culture. In Vitro, the
transduced mesangial cells showed a reduced mitogenic response to fetal
calf serum and were insensitive to induction of matrix metalloproteinase-9
(MMP-9) by the proinflammatory cytokine IL-I /3. To examine whether
glomeruli which express active TGF-131 in vivo are insensitive to these
same stimuli, TGF-13 transfectants were transferred into normal rat
glomenili via renal artery injection. After 24 hours, isolated glomeruli
containing transfectants exhibited TGF-/3 bioactivity, a reduced mitogenic
response, and repressed expression of MMP-9 in response to IL-113. We
further examined the responses of these chimeric glomeruli to an in vivo
mitogenic stimulus by transferring TGF-f3 transfectants into glomeruli of
kidneys one day after the induction of anti-Thy-i nephritis. The mitogenic
activity of isolated glomeruli was examined four days after the cell
injection. Compared to unmodified or mock cell-containing glomeruli, the
in vivo mitogenic activity of glomeruli containing TGF-13 transfectants was
significantly repressed. Furthermore, cellular outgrowth from nephritic
glomeruli expressing active TGF-13i was also suppressed ex vivo compared
to controls. These data indicate that TGF-f3i inhibits mitogenesis and IL-i
response of the glomerulus and may, in part, act as a potential early
suppressor of glomerular inflammation.
Transforming growth factor-a (TGF-13) has been regarded as a
harmful cytokine which induces accumulation of extracellular
matrix during the process of glomerular inflammation [1]. How-
ever, this molecule has the potential to be anti-inflammatory by
virtue of its effect on infiltrating cells as well as resident cells. For
example, TGF-!3 is known to be a suppressor of proliferation and
activation of lymphocytes [21. Although TGF-/3 may facilitate
migration of monocytes [3], this cytokine strongly inhibits activa-
tion of macrophages which play a pivotal role in the pathogenesis
of glomerular injury [4, 5]. TGF-/3 also protects the cells from
acute injury by opposing the effects of inflammatory mediators
such as IL-i and tumor necrosis factor-a (TNF-a) [6—9]. Further-
more, TGF-13 directly inhibits the proliferative response of a wide
range of cells including renal glomerular and tubular cells [10—
12]. These lines of evidence suggest that TGF-/3 may have the
potential for attenuation of glomerular inflammation.
By systemic administration of substances which neutralize
TGF-f3 activity, Border and coworkers showed that TGF-13 plays
a crucial role in matrix accumulation of the glomerulus during the
acute glomerulonephritis [13—151. Using liposome-mediated di-
rect gene transduction, Isaka and coworkers also reported that
transient expression of TGF-13 induced glomerular matrix expan-
sion in vivo [16]. However, several questions remain unanswered
regarding the pathophysiological roles of TGF-f3 in glomerular
injury: (i) Does TGF-j3 act as an inhibitor of cell proliferation
during the process of glomerular inflammation? (ii) How does
TGF-13 modulate the responses of glomerular cells to proinflam-
matory stimuli in Vitro and in vivo? The present study addressed
these questions.
To examine the function of specific molecules in the glomeru-
lus, systemic administration of bioactive substances could be
tested. However, the most sophisticated approach is to utilize
systems which allow target molecules to be accumulated only in
the glomerulus, particularly if the molecules have profound and
diverse effects on cells in other organs. Using the glomerular
mesangial cell as a vector for gene delivery, we previously
reported a gene transfer system which specifically targets the
glomerulus [17]. In this method, mesangial cells are engineered ex
vivo to allow for the expression of a foreign gene product and
injected into the kidney via the renal artery. This mesangial cell
vector system achieves efficient and site-specific delivery of a
foreign gene into the glomerulus and allows for its sustained
expression in vivo. Using this gene transfer approach, we here
demonstrate a novel glomerular action of TGF-131, that is, its
suppressive effects on the mitogenic response and on the release
of IL-I-inducible metalloproteinase by the glomerulus in normal
and pathological situations.
Methods
General experimental strategy
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Using an in vivo gene delivery system, we examined the
anti-inflammatory potential of TGF-(31 in the glomerulus. We
focused on its effects on the glomerular mitogenesis and on the
generation of IL-i-inducible metalloproteinase by glomerular
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cells. A mutated gene which encodes the active form of TGF-J31
was introduced into cultured rat mesangial cells. The responses of
stable transfectants to fetal calf serum (FCS) and the proinfiam-
matory cytokine IL-1/3 were examined. The TGF-f31 transfectants
were then transferred into normal rat glomeruli via renal artery
injection. Isolated glomeruli were examined for active TGF-13
secretion and for their responses to mitogen and IL-113. Trans-
fectants were also transferred into the glomeruli of kidneys
subjected to anti-Thy-i nephritis, and the mitogenic activity of the
isolated glomeruli was investigated.
Establishment of stable transfectants
A porcine TGF-j31 cDNA was subjected to site-directed mu-
tagenesis to modify Cys223 and Cys225 to serines in the pro-
region of TGF-131 in order to allow for the expression and export
from the cells of active TGF-pl, as reported [18]. An expression
plasmid, pH/3TGFneo, was constructed by subcloning of 1.3 kb
BglII fragment of the mutated TGF-/31 cDNA from a pPK9a
plasmid [181 into a BamHI site of the eukaryotic expression
plasmid, pHI3APr-lneo [19] in a sense orientation. This allows for
expression of the mutant TGF-131 under the control of the -actin
promoter.
Rat mesangial cell cultures were established from isolated renal
glomeruli of a male inbred Fisher rat (F344; 5 weeks, Harlan Olac
Ltd., Bicester, UK) as described before [20]. In brief, mesangial
cells were cultured from glomeruli in Dulbecco's MEM/F-12
(DME-F12; GIBCO BRL, Gaithersburg, MD, USA) supple-
mented with 100 U/mI of penicillin G, 100 jtg/ml of streptomycin,
0.25 g/ml of amphotericin B, and 15% FCS. After the fourth
passage, a cell clone FM14 was established by a limiting dilutional
method and identified as being of mesangial cell phenotype as
described elsewhere [20]. Using a modified calcium phosphate
co-precipitation method [211, FM14 was transfected with the
pH/3TGFneo or the pH/3APr-lneo as described previously [22].
Stable transfectants were selected in the presence of neomycin
analogue G418 (0.75 mg/mI: Sigma Immunochemicals, St. Louis,
MO, USA). TGF-13-expressing clones TG6 and TG1I, as well as
mock transfectants MO2 and M05, were established from neo-
mycin-resistant clones. Successful expression of the mutant
TGF-f31 gene was confirmed by Northern analysis [23]. We also
transfected FM14 with expression plasmids, pRc/CMV (In vitro-
gen, San Diego, CA, USA) and pFEBOS1O5GEL [24], which
introduce a neomycin phosphotransferase gene and a mouse 105
kD gelatinase B gene, respectively. A stably-transfected reporter
clone 1O5GEL-8 was established from neomycin-resistant cells
using gelatin zymography as the assay method for expression. This
is described below. This reporter cell was used for the confirma-
tion of successful in vivo gene transfer and secretion of the
exogenous gene product within the glomerular microenviron-
ment.
Recombinant TGF-f31 produced by transfectants
Using immunoblot analysis, we first examined whether the
transfected cells secreted the active form of TGF-31 in the culture
media. TG6 or M02 cells (2 X 106) were cultured in 3 ml of 1%
FCS/DME-F12 for 40 hours. The conditioned media were centri-
fuged, and 1 ml of each supernatant or fresh 1% FCS/DME-F12
was precipitated with 1 ml of 10% trichloroacetic acid. After
centrifugation, each pellet was dissolved in 10 M1 of 0.5 N NaOH,
electrophoresed on a 10% polyacrylamide gel, and transferred
electrophoretically onto a nitrocellulose membrane (Schleicher
and Schuell, Dassel, Germany) as described previously [251.
Immunoblot analysis was performed using an anti-human TGF-131
antibody (1:1000 dilution; Promega, Southampton, UK), Vec-
tastain ABC Kit (Vector Laboratories, Peterborough, UK) and
peroxidase substrate kit AEC (Vector Laboratories) following the
protocols provided by the companies. As a positive control for 25
kD active TGF-/3i, human TGF-pl (Genzyme, Cambridge, MA,
USA) was used.
We next tested the biological activity of the recombinant
TGF-131 produced by the transfectants. Conditioned media con-
taining 1% FCS were prepared from cultures of TGF-f31 trans-
fectants or mock transfectants, and bioactivity of TGF-13 was
examined by growth inhibition assay using the mink lung epithelial
cell line, CCL-64 (European Collection of Animal Cell Cultures,
Salisbury, UK) [26]. In brief, CCL-64 cells were seeded in 24-well
plates at a density of 5 X io cells/well. After incubation for 24
hours in the presence of 10% FCS, cells were further incubated in
1% FCS/DME-F12 for 24 hours and then exposed to test media.
To prepare test media, confluent culture of each transfectant (2 X
106 cells) in 100 mm plates was incubated in 4 ml of 1%
FCS/DME-F12 for 24 hours, and 500 l of diluted conditioned
media (1:3, 1:9, 1:27) with 1% FCS/DME-F12 were added to
CCL-64 cells. After 48 hours, [3H]-thymidine (1 /LCi/well) was
added, incubated for three hours, and incorporation of radioac-
tivity was measured by liquid scintillation counting. As standards,
human platelet TGF-/31 (Sigma Immunochemicals; 20 to 500 pM)
was used.
Effect of TGF-pl transfection on mitogenesis and IL-i response of
cultured mesangial cells
Using the established clones, mitogenic responses were exam-
ined in vitro. Transfectants suspended in 10% FCS/DME-F12
were seeded in 24-well plates at a density of 2 X io cells/well.
After incubation for 24 hours, cell growth was arrested by serum
depletion (0.5%) for 48 to 72 hours. The cells were then exposed
to 5% FCS for 24 hours, pulsed with 1 MCi/well of [3H]-thymidine
for 6 to 24 hours, and incorporation of radioactivity was mea-
sured. To examine the effect of externally added TGF-f31 on
mesangial cell mitogenesis, 100 M TGF-f31 was added to a mock
transfectant M02 during the period of serum depletion, and
[3H]-thymidine incorporation was assessed as described above
following the exposure to FCS. MO2 and TG6 cells suspended in
10% FCS/DME-F12 were also seeded into 24-well plates at a
density of 2 x i0 cells/well, and total cell number was counted
every other day for up to eight days during the course of culture.
All assays were performed in quadruplicate.
We have reported that matrix metalloproteinase-9 (MMP-9;
gelatinase B) is markedly induced in mesangial cells by the
proinflammatory cytokine IL-113 [271. Since activity of metallopro-
teinases can be detected easily and sensitively by zymographic
analyses, we used MMP-9 as an indicator of the IL-i response by
mesangial cells. Confluent cultures of each transfectant in 6-well
plates were exposed to 10 ng/ml of recombinant human IL-i13 (a
gift from Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan) in
the presence of 10% FCS. After 24 hours, medium was replaced
with 700 tl of 0 to 1% FCS/DME-F12 and further incubated for
24 hours. To examine the effect of exogenous TGF-/3, ito 5 ng/ml
of human TGF-/31 and 10 ng/ml of IL-1f3 were concurrently added
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to the mock transfected cells in the presence of 1% FCS with or
without TGF-131 pre-treatment (1 or 5 ng/ml; 24 hr). Conditioned
media were collected after 48 hours, centrifuged, and superna-
tants were used for zymography.
Zymographic analysis of MMP-9 was performed as reported
previously [27, 28]. In brief, aliquots of conditioned media (5 to 8
pJ) were mixed with same amounts of sample buffer and applied
to 10% acrylamide gels containing 0.1% gelatin. After electro-
phoresis, SDS was removed from the gels by incubation in 2.5%
Triton X-100 at room temperature for 30 minutes, and the gels
were further incubated at 37°C overnight in a developing buffer
(pH 7.6) containing 50 mM Tris, 0.2 M NaC1, 5 mivi CaC12, and
0.02% Brij 35. Gels were stained in a solution containing 30%
methanol, 10% glacial acetic acid and 0.5% Coomassie G250 and
destained in the same solution without dye.
In vivo transfer of TGF-131 gene and bioactivily of TGF-J31
produced by chimeric glomeruli
Using the mesangial cell vector system [17], we engineered rat
glomeruli to allow for the secretion of active TGF-pl. TGF-13-
transfected mesangial cells (TG6) or mock transfected cells
(M02) (1 X 106 cells) were injected into the left kidneys of adult
male Fisher rats (200 to 300 g; total 10 rats) via renal artery
injection as described previously [17]. After 24 hours, both
kidneys were removed and the glomeruli isolated.
To examine whether glomeruli containing TGF-13 transfectants
continuously secrete active TGF-/31, we assessed TGF activity on
conditioned media from isolated glomeruli containing TG6 or
M02 cells. Glomeruli suspended in 1% FCS/DME-F12 were
transferred into 96-well round bottom plates (Greiner Labortech-
nik Ltd., Gloucestershire, UK) at a density of 2 >< io glomeruli!
200 tl per well. After 48 hours incubation, media were collected,
centrifuged, and 100 jil of each supernatant was mixed with 200 pJ
of fresh 1% FCS/DME-F12 and added to CCL-64 cells. TGF-/3
bioassay was performed as described above.
To ascertain that the engineered vector cells can efficiently
release a recombinant molecule within the glomerulus, the re-
porter clone 1O5GEL-8 which secretes 105 kD gelatinase was
used; these cells (5 x iO cells) were injected into the kidney (3
rats), and zymographic analysis was performed on conditioned
media from 2 x iO isolated glomeruli incubated in 500 jd of 1%
FCS/DME-F12 for 24 to 96 hours.
Responses of chimeric glomeruli containing TGF-pl transfectants
to mitogenic stimuli and to IL-i in vitro
The mitogenic response to FCS of isolated glomeruli containing
TG6 cells or M02 cells was examined. Glomeruli suspended in
20% FCS/DME-F12 were transferred into 96-well round bottom
plates at a density of 2 X i0 glomeruli/200 jfl per well. After 48
or 72 hours, 0.5 Ci of [3HJ-thymidine was added to each well,
further incubated for 24 hours, and incorporation of thymidine
was assessed. The effect of TGF-J31 on glomerular cell mitogen-
esis was also assessed by externally adding TGF-/31; that is,
unmodified glomeruli suspended in 1% FCS/DME-F12 were
dispensed into 96-well plates and incubated for 24 hours in the
presence of 0, 5, 50 nglml TGF-31. Half of each medium was then
replaced with 39% FCS/DME-F12. After 72 hours incubation,
cells were exposed to [3H]-thymidine (0.5 j.Ci/well) for 8 to 24
hours, and incorporation of radioactivity was evaluated. Assays
were performed in quadruplicate.
Chimeric glomeruli containing transfectants were also exposed
to IL-1f3. Unmodified glomeruli or glomeruli containing TG6 or
M02 cells suspended in 1% FCS/DME-F12 (2 >< i0 glomeruli!
200 p! per well) were incubated for 48 hours with or without 10
ng/ml of IL-lp. Expression of MMP-9 was examined on condi-
tioned media using gelatin zymography as described. For North-
ern analysis, unmodified glomeruli or TG6-containing chimeric
glomeruli (2 x io glomeruli) isolated from same rats were
incubated in 1% FCS for 24 hours and then stimulated with 20
ng/ml of IL-1/3 for 48 hours. Northern blot analysis was performed
on MMP-9 expression using a mouse gelatinase B cDNA, as
described before [27].
Effect of TGF-/31 gene transfer on mitogenesis in glomeruli
subjected to acute glomerulonephritis
An anti-mesangial cell monoclonal antibody 1-22-3 [29], which
recognizes the Thy-i-associated molecule on the surface of rat
mesangial cells, was used to induce acute proliferative glomeru-
lonephritis in rats. 1-22-3 was prepared as described before [17].
The antibody was dissolved in PBS at a final concentration of 500
agIml, and an aliquot of 1 ml was injected into the tail vein. 1 X
106 TGF-/31-transfected cells (TG6) or mock transfected cells
(M02) were injected into the left kidney of adult Fisher rats (total
12 rats) one day after the 1-22-3 treatment. After four days, both
kidneys were removed and processed for glomerular isolation.
The yield of glomeruli isolated from single kidney was constantly
between 3.0 x i04 and 4.5 x i04 (mean value 3.7 X 10), and the
purity was more than 96% (98.0 1.3%). No differences in the
yield of isolated glomeruli were detected between TG6- or
M02-injected kidneys and uninjected kidneys. The mitogenic
response of isolated glomeruli containing transfectants were
examined as follows. Glomeruli suspended in 1% FCS/DME-F12
were transferred into 96-well round bottom plates at a density of
2 x i03 glomeruli/200 jil per well. Glomeruli were then incubated
in the presence of [3H]-thymidine (0.5 jiCi/well) for 18 hours, and
incorporation of radioactivity was evaluated.
Isolated glomeruli were also dispensed into 24-well plates at a
density of 4 X iO glomeruli per well and subjected to culturing in
the presence of 20% FCS. After 10 to 12 days, the mitogenic
activity of outgrowing cells was examined by [3H]-thymidine
incorporation. To confirm that the transferred cells survived and
continuously secreted active TGF-pl, the glomerular cultures in
six-well plates were exposed to G418 (0.75 mg/mI) for two weeks,
and conditioned media of the selected cells were used for TGF-/3
bioassay.
Data presentation and statistical analysis
Among the various experiments each of which was repeated two
to four times, a representative result is shown. All data are
expressed as means SE. Statistical analysis was performed using
the Mann-Whitney test to compare data in different groups. A P
value of < 0.05 was used to indicate a statistically significant
difference.
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Fig. 1. Expression and secretion of biologically
active TGF- /31 in the established transfectants. A
rat mesangial cell clone FM14 was transfected
with a mutant TGF-/31 expression plasmid
pHf3TGFneo or a mock construct pHj3APr-
lneo using a modified calcium phosphate co-
precipitation method. Stable transfectants were
selected in the presence of a neomycin
analogue G418, and TGF-/3-expressing clones
TG6 and TG11, as well as mock transfectants
M02 and M05, were established. A. Northern
blot analysis of the TGF-/31 transcript. The
arrow on the right indicates expression of the
exogenous TGF-/31 gene. The position of 18S
ribosomal RNA is shown on the left. Staining
of ribosomal RNA5 with ethidium bromide is
shown as a loading control. B. Immunoblot
analysis of the exogenous TGF-/31 protein in
conditioned media. Fresh culture media
[cell(—)] or conditioned media derived from
TG6 or M02 cells were precipitated with 10%
trichloroacetic acid, electrophoresed on a 10%
polyacrylamide gel, transferred
electrophoretically onto a nitrocellulose
membrane and stained with anti-human TGF-
/31 antibody which recognizes the active form of
TGF-/31. The color reaction was performed
using an immunoperoxidase method. The
positions of standard molecular-weight markers
(30 and 22 kD) are shown on the left. The
arrow "25 kD" on the right indicates the
expressed active TGF-/31. C. Bioassay of TGF-/3
activity in conditioned media. TGF-/3 bioactivity
was assessed by a growth inhibition assay using
the mink lung epithelial cell line, CCL-64. As a
standard human TGF-/31 (20 to 500 pM) was
used (left panel). Conditioned media from
TGF-/31 transfectants (TG6 and TG11) or
mock transfectants (M02 and M05) were
diluted at () 1:3, () 1:9 or () 1:27, and
incorporation of [3H]-thymidine was measured
(right panel).
Results
Expression and secretion of biologically active TGF-j31 in stably
transfected mesangial cells
Stable transfectants, TG6 and TG1 1, which secrete the active
form of TGF-f31 were established. Normally, cultured rat mesan-
gial cells express a 2.5 kb TGF-/31 mRNA 1301. Northern blot
analysis detected this 2.5 kb transcript in TG6 and TG11 as well as
in the mock transfected clones, M02 and M05. A 1.5 kb
transcript of the exogenous TGF-/31 gene was detected exclusively
in TGF-f3 transfectants, abundantly in TG6 and weakly in TG11
(Fig. 1A). Immunoblot analysis of conditioned media from TG6
detected a 25 kD band which corresponds to the active form of
TGF-j31 [31) (Fig. 1B). A weak 25 kD band was also detectable in
the media from M02, but not in fresh media, suggesting that, to
some extent, the endogenous latent TGF-p may be converted to
the active form in culture, as reported previously [30]. The
secreted recombinant TGF-j31 was biologically active, since con-
ditioned media from TGÔ and TG11 inhibited proliferation of the
TGF-/3-sensitive indicator cell, CCL-64, in a concentration-depen-
dent manner (Fig. 1C). The estimated concentration of active
TGF-/31 in conditioned media was 250 to 330 M in TG6 and 130
to 160 M in TG11 (5 x io cells/mi for 24 hr), which was closely
associated with the expression levels of the exogenous gene
transcript. Although undiluted conditioned media from mock
transfected cells inhibited the mitogenesis of CCL-64 by 45 to
65% (data not shown), no detectable TGF-/3 activity was observed
in the diluted conditioned media at more than three times.
Effect of TGF-f31 transfection on mitogenesis and IL-i response of
cultured mesangial cells
To elucidate whether mesangial cells expressing active TGF-/31
show the same blunted response to mitogens as they do when
exposed to exogenous TGF-131 [11, 30], we examined the mito-
genie response of the transfected cells in vitro. [3H]-thymidine
incorporation assay revealed that TGF-f31 transfectants, TG6 and
TG1I, exhibited blunted responses to FCS compared to the mock
transfectants, M02 and M05 (Fig. 2A). The [3H]-thymidine
incorporation rates were 56.1 1.1% in TG6 and 64.3 3.0% in
TGI 1 compared to the mean value of the mock transfected cells
(100%). This inhibitory effect was reproduced by adding approxi-
mately 100 M TGF-f31 to the culture of M02. The growth inhibitory
effect was further confirmed by counting cell number. As shown in
Figure 2B, TG6 consistently exhibited a lower total cell number than
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Fig. 2. Mitogenic responses of TGF-j31 transfectants. A. Growth-arrested
transfectants were exposed to 5% FCS for 24 hours, and incorporation of
[3H1-thymidine was examined. To investigate the effect of externally added
TGF-pl on mesangial cell mitogenesis, 100 pvi TGF-131 was added to the
mock transfectant M02, and thymidine uptake was examined under the
stimulation of FCS. The data are presented as means SE. Asterisks show
statistically significant differences (P < 0.05) compared to the values of
both mock transfectants. Assays were performed in quadruplicate. The
result shown is representative of three independent experiments. B. M02
and TG6 cells were seeded into 24-well plates at a density of 2 x IO
cells/well, incubated in the presence of 10% FCS, and cell number was
counted every other day for up to day 8 during the course of culture.
Symbols are: (0) M02; (•) TG6.
M02 throughout the period of observation. Statistically significant
differences were observed at day 6 and day 8.
It has been reported that TGF-/3 inhibits cellular responses to
proinflammatory stimuli such as IL-I and TNF-a [7—9, 321. Using
the established transfectants, we next examined whether TGF-j3
can modulate mesangial cell responses to IL-i which has been
evoked as a mediator of glomerular diseases [33J. In this study, we
used the expression of MMP-9 as an indicator of IL-i response.
Normally, cultured rat mesangial cells produce MMP-2 (gelati-
nase A), whereas little expression of MMP-9 is observed. After
the stimulation by IL-1j3, however, MMP-9 was markedly induced
without induction of MMP-2, and once stimulated, the expression
continued at least for three days even in the absence of IL-ip (Fig.
3A). Confluent cultures of transfected cells were incubated with
or without IL-i/3 for 24 hours, and conditioned media were
collected for the following 24 hours and subjected to gelatin
zymography. In the mock transfectant M02, MMP-9 was mark-
edly induced by IL-1j3. In contrast, only a limited induction of
MMP-9 was observed in both TGF-13 transfectants, TG6 and
TG11 (Fig. 3B). We further examined the effect of exogenous
TGF-13i on IL-i-stimulated mock transfectants. As shown in
Figure 3C, externally added TGF-13i also suppressed induction of
MMP-9 by IL-i13 in a dose-dependent manner. The inhibitory
effect was further enhanced by pretreatment with TGF-/31 for 24
hours. In contrast, secretion of constitutively expressed MMP-2
was increased by TGF-pl transfection or exogenously added
TGF-131 (Fig. 3B and C).
Transfer of TGF-f31 gene into glomeruli in vivo and TGF-13
bioactivity of chimeric glomeruli
To confirm an effective gene delivery into the glomerulus in
inbred Fisher rats, we first injected the established reporter clone
1O5GEL-8 which expresses and secretes mouse 105 kD gelati-
nase B (Fig. 4, upper panel). The reporter cells were suspended
in I ml of DME-Fi2 and injected into the left kidney via the
renal artery. Zymographic analysis was performed on condi-
tioned media of isolated glomeruli from both kidneys. As
shown in Figure 4 (lower panel), abundant expression of 105
kD gelatinase was observed in conditioned media of glomeruli
from the 1O5GEL-8-injected kidney (modified G.) but not in
those from the non-injected contralateral kidney (unmodified
G.). This finding demonstrated the feasibility of delivering an
exogenous secretory molecule into the glomerulus using the
mesangial cell vector system.
We next engineered the rat glomeruli to allow for the sustained
secretion of the active TGF-13i. TGF-f3 transfected TG6 or mock
transfected M02 cells were transferred into the left kidneys via
renal artery injection. After 24 hours, TGF-p activity was exam-
ined on conditioned media from isolated glomeruli containing
TG6 or M02 cells. Compared to unmodified or M02-transferred
glomeruli, conditioned media from TG6-containing glomeruli
exclusively exhibited a level of TGF-13 activity of approximately 40
to 60 pM.
Responses to mitogenic and IL-i stimuli of isolated glomeruli
containing TGF-131 transfectants in vitro
The mitogenic response to FCS of the isolated glomeruli
containing TG6 or M02 was examined. Glomeruli were exposed
to 20% FCS for two or three days, and incorporation of [3H]-
thymidine was assessed. Glomeruli containing TG6 cells exhibited
a significant reduction of thymidine incorporation compared to
unmodified glomeruli (23.2 2.1%) or glomeruli containing
0 2 4 6 8
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Fig. 3. Induction of matrix metalloproteinase-9 (MMP-9, gelatinase B) by IL-i /3 in untransfected or TGF-/31-transfected mesangial cells. A. Induction of
MMP-9 in untransfected mesangial cells. Confluent mesangial cells were stimulated with 10 nglml IL-1/3 in the presence of 1% FCS for 24 hours.
Conditioned media obtained before or after the stimulation were collected every 24 hours up to 96 hours, and expression of MMP-9 was analyzed by
gelatin zymography. The positions of MMP-9 and MMP-2 (gelatinase A) are indicated on the left. B. Induction of MMP-9 in transfectants. Transfectants
were cultured in the absence (—) or presence (+) of IL-1/3 for 24 hours. Media were then replaced with fresh DME-F12, further incubated for 24 hours,
and the conditioned media were subjected to zymographic analyses. C. Effect of TGF-j31 added to the mock transfectant M02 on the induction of
MMP-9. TGF-f3(1 to 5 ng/ml) and IL-i/I were concurrently added to the culture of M02 with or without TGF-/31 pre-treatment (1 ng/ml; 24 hr). After
24 hours, conditioned media were collected and used for zymography. Each result is from 2 to 3 independent experiments.
mock transfectants (18.8 2.2%) (Fig. 5A). M02-containing
glomeruli also showed a slight but consistent decline of mitogenic
activity (not statistically different) compared to unmodified gb-
meruli. Exogenous TGF-/31 also reduced the mitogenic response
of unmodified glomeruli in a dose-dependent manner (Fig. 5B).
These findings indicated that active TGF-p1 acts as a suppressor
of mitogenesis in the glomerulus.
Unmodified glomeruli or glomeruli containing TG6 or M02
cells were exposed to IL-1/3, and expression of MMP-9 was
examined by gelatin zymography (Fig. 6A). Normally, isolated
glomeruli expressed moderate level of MMP-9 as well as MMP-2.
When stimulated with IL-1/3, the expression of MMP-9 was
up-regulated without increase of MMP-2 level, as was observed in
cultured mesangial cells (Fig. 3A). However, in the gbomeruli
containing TG6 cells, the induction of MMP-9 by IL-113 was
markedly repressed compared to mock cell-containing glomeruli
and modestly to unmodified glomeruli. Glomeruli containing
M02 cells exhibited enhanced IL-i response conceivably due to
additive response of the transferred cells.
IL-I induction of MMP-9 in chimeric glomeruli was further
examined at a transcriptional level (Fig. 6B). Unmodified glomer-
uli or TG6-containing glomeruli were stimulated with IL-1f3 for 48
hours, and Northern blot analysis was performed on MMP-9
expression. Compared to unmodified gbomeruli, the basal level of
MMP-9 was not obviously affected by the transfer of TGF-/31
gene. When stimulated with IL-I/I, the mRNA expression of
MMP-9 was up-regulated in unmodified glomeruli. However, in
the chimeric glomeruli expressing active TGF-p1, induction of
MMP-9 was markedly suppressed. These findings showed that
TGF-131 secreted within the gbomeruli repressed the IL-i re-
sponse of the glomerulus in vitro.
Effect of TGF-/31 gene transfer on mitogenesis in glomeruli
subjected to acute glomerulonephritis
TG6 or mock transfected M02 cells were injected into the left
kidney of Fisher rats one day after the treatment with the
monoclonal antibody 1-22-3, which induces mesangiolysis fol-
lowed by acute proliferative glomerulonephritis. After four days,
the mitogenic activity of isolated gbomeruli was assessed in the
absence of growth stimuli. Normal unmodified glomeruli exhib-
ited little incorporation of [3H-thymidine, whereas 1-22-3-treated
glomeruli showed marked mitogenic activity (Fig. 7A). When the
TG6 cells were transferred into the nephritic gbomeruli, however,
the mitogenic activity was repressed. The inhibition was 35.0
4.1% versus unmodified gbomeruli and 27.0 4.6% versus
M02-containing glomeruli. Mitogenic activity was also examined
on the cellular outgrowth from the gbomeruli ex vivo. As shown in
Figure 7B, [3H1-thymidine incorporation of the cells from TG6-
containing gbomeruli was 57.9 to 61.9% of that of the cells from
unmodified or M02-containing control gbomeruli when examined
after 12 days in culture.
To examine whether the transferred transfectants survived and
continuously expressed active TGF-131, cells were selected in the
presence of 0418. Numerous neomycin-resistant colonies were
found in the cultures of M02- or TG6-transferred glomeruli but
not in uninjected glomeruli (Fig. 8A). Conditioned media from
the selected TG6 colonies, but not M02 colonies, exhibited high
level of TGF-f3 bioactivity (Fig. 8B). These findings confirmed the
survival of vector cells within the glomerulus during the study and
sustained release of active TGF-J31 by the TG6 cells, leading to
the blunted mitogenic response of the gbomerulus in vivo.
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Fig. 4. Expression of exogenous 105 kDgelatinase in isolated glomeruli after
the transfer of vector cells. Mesangial cells were transfected with an
expression plasmid pFEBOS1O5GEL which introduces a mouse 105 kD
gelatinase B gene. Established reporter cells 1O5GEL-8 (5 x io cells)
were injected into the rat kidney, and zymographic analysis was performed
on conditioned media from 2 x io isolated glomeruli incubated in 500 pJ
of 1% FCS/DME-F12 for 48 hours. Upper panel: gelatin zymography on
conditioned media from untransfected cell (FM14) with or without IL-1/3
stimulation, or from 1O5GEL-8 cells. Lower panel: zymographic analysis
on media conditioned with isolated glomeruli from the uninjected kidney
(unmodified G.) or from the cell-injected kidney (modified 0.). Zymo-
gram of the conditioned medium from 1O5GEL-8 cells is shown on the
right. The result shown is representative of three experiments.
Discussion
TGF-f3 has been implicated as an important mediator of
glomerular injury, especially of extracellular matrix deposition
and glomeruloscierosis, based on in vitro experiments or on
techniques used to detect expression of TGF-f3 in the affected
glomeruli. Important studies have also been conducted to eluci-
date the in vivo function of TGF-/3, focusing on matrix accumu-
lation in the glomerulus [13, 15, 16]. However, still unknown is
whether TGF-/3 acts as a mitogenic inhibitor within the glomer-
ulus and how this molecule modulates the responses of glomeru-
lar cells to proinflammatory stimuli in vitro and in vivo. Using the
mesangial cell vector as a gene transfer system, we attempted to
answer these questions. In this report, we demonstrate that
mesangial cells and glomeruli expressing active TGF-pl have
blunted sensitivity to mitogenic and proinflammatory stimuli in
vitro and in vivo. These findings suggest that locally produced
TGF-J31 may, at least in part, contribute to the prevention of or
recovery from acute injury in the glomerulus by reducing mito-
genesis of glomerular cells and/or by opposing the effect of local
inflammatory cytokines such as IL-1f3.
Several investigators have reported the effects of TGF-13 on
proliferation of cultured glomerular cells [34—37]. Generally, this
molecule suppresses proliferation of endothelial, mesangial, and
epithelial cells in culture, conceivably via affecting components of
cell-cycle machinery [38]. However, this inhibitory effect might be
reversed under different culture conditions, depending on cell
density or anchoring [34, 39]. It has been unclear how TGF-13
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Fig. S. Effect of TGF-pl on mitogenic response of the glomerulus. A.
Mitogenic response of isolated glomeruli containing TGF-131 transfec-
tants. Isolated glomeruli transferred with TG6 cells (TG6-glom.) or M02
cells (M02-glom.) (1 X 106 cells) were suspended in 20% FCS/DME-F12
and transferred into 96-well round bottom plates at a density of 2 >< io
glomeruli/200 xl per well. After 48 or 72 hours, 0.5 sCi of [3H]-thymidine
was added to each well, incubated further for 24 hours, and incorporation
of thymidine was assessed. The asterisk indicates statistically significant
differences (P < 0.05) compared to both unmodified glomeruli and
M02-containing glomeruli. Assays were performed in quadruplicate. B.
Effect of externally-added TGF-131 on glomerular cell mitogenesis. Gb-
meruli from uninjected kidneys were suspended in 1% FCS/DME-F12 and
dispensed into 96-well plates. After the incubation for 24 hours in the
presence of 0, 5, or 50 ng/ml TGF-31, half of each medium was replaced
with 39% FCS/DME-F12. After 72 hours, cells were exposed to [3H]-
thymidine, and incorporation of radioactivity was evaluated. The asterisk
indicates statistically significant differences (P < 0.05) compared to the
value in the absence of TGF-f31. Each experiment was performed 2 to 3
times.
modulates the proliferation of the cells located in the normal
glomerulus. In this report, we showed that internally secreted or
externally added active TGF-/31 inhibits the mitogenic response of
cells within the normal glomerulus. Furthermore, we found that
mitogenesis in the glomerulus subjected to acute glomerulone-
phritis could also be suppressed by internally secreted TGF-pl.
This anti-mitogenic potential may be due to a direct effect on
resident glomerular cells, particularly mesangial cells, as demon-
strated in this report. Another possible mechanism might be the
inhibitory effects on infiltrating cells, especially on macrophages,
which accumulate in anti-Thy-i nephritis [401. In this experimen-
tal model, macrophage depletion protects the glomerulus against
mesangial cell proliferation [41], suggesting that macrophages
play a crucial role in the in vivo proliferative response of mesan-
gial cells. TGF-/3 is known to be a prominent "macrophage
deactivator" which suppresses the release of several inflammatory
mediators [4, 42, 43]. Recently, we found that TGF-31 strongly
inhibits expression of IL-1/3, IL-6 and TNF-a in murine macro-
phages stimulated by lipopolysaccharide (M. Kitamura, manu-
script submitted). TGF-f3 may, therefore, suppress glomerular cell
mitogenesis in part by inhibiting release of cytokines by activated
local macrophages.
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Fig. 6. IL-I response of isolated chimeric glomeruli containing TGF-pI
transfectants in vitro. A. Zymographic analysis of MMP-9 expression.
Unmodified glomeruli or glomeruli containing TG6 or M02 cells sus-
pended in 1% FCS/DME-F12 (2 >< io glomeruh/200 /61 per well) were
incubated for 48 hours with or without 10 ng/ml of IL-113. Expression of
MMP-9 was examined on conditioned media using gelatin zymography.
The result shown is representative of three experiments. B. Northern blot
analysis of MMP-9 expression. Unmodified glomeruli or TG6-containing
glomeruli (2>< io glomeruli) were incubated in 1% FCS/DME-F12 for 24
hours and stimulated with 20 ng/ml of IL-lp for 48 hours. Northern blot
analysis was performed using a mouse MMP-9 eDNA. Expression of
f3-actin is shown as a loading control.
Fig. 7. Effect of TGF-/31 gene transfer on mitogenesis of glomeruli subjected
to acute glomerulonephritis. An anti-mesangial cell monoclonal antibody
1-22-3 (500 .rg) was injected into the tail vein of rats, and TG6 or M02 (1
x 106 cells) was injected into the left kidneys after 24 hours. After four
days, both kidneys were removed and processed for glomerular isolation.
A. Isolated glomeruli suspended in 1% FCS/DME-F12 were transferred
into 96-well round bottom plates at a density of 2 >< 10° glomeruli/200 j.rl
per well. Glomeruli were then incubated in the presence of [°H}-thymidine
for 18 hours, and incorporation of radioactivity was evaluated. Incorpo-
ration of thymidine into normal glomeruli without 1-22-3 treatment is
shown on the left. The asterisk indicates statistical significance (P < 0.05)
of the difference compared to the both values of unmodified glomeruli and
M02-containing glomeruli. Assays were performed in quadruplicate. B.
Isolated glomeruli were dispensed into 24-well plates at a density of 4 )<
10° glomeruli per well and subjected to culture in the presence of 20%
FCS. After 12 days, mitogenic activity of outgrowing cells was assessed by
[°H1-thymidine incorporation. Each result shown is representative of four
independent experiments.
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Fig. 8. Recoveiy of the transferred vector cells from isolated chimeric
glomeruli in culture. Four days after the cell injection, glomeruli were
isolated from cell-injected or uninjected kidneys, cultured in 6-well plates,
and the outgrowing cells were selected in the presence or absence of G418
(0.75 mg/mI) for two weeks. A. Hematoxylin staining of the outgrowing
cells with (+) or without (—) G418 selection. B. TGF-f3 bioactivity
expressed in the neomycin-resistant cells recovered from M02- or TG6-
injected glomeruli. G418-selected cells were cultured in 500 t1 of 1%
FCS/DME-F12 for 48 hours. The conditioned media were diluted three
times with fresh 1% FCS/DME-F12, and TGF- bioactivity was assessed
using CCL-64 cells.
In our study, externally added TGF-31 as well as the transfer of
the active form of the TGF-/31 gene inhibited mitogenic response
of the glomerulus. However, Isaka and co-workers previously
reported that in vivo transfection of TGF-/31 gene induced
significant hypercellularity in the glomerulus [16]. The reason for
this discrepancy is currently unknown. One possibility may be the
difference in methods utilized for evaluation. In general, increased
cellularity in the glomerulus is due to infiltration of leukocytes as
well as proliferation of intrinsic cells. Incorporation of [3H]-
thymidine, used in our study, mainly reflects the latter, whereas
histological cell counting includes both. Since TGF-/3 is known to
be a chemoattractant [3], the increased cellularity observed in the
previous report might be due to leukocyte infiltration. An another
possibility may be due to the difference in the transgenes utilized.
When a wild type TGF-f3 cDNA is introduced into the glomeru-
lus, the secreted molecule requires to be converted to the active
form before exerting its biological activity [10]. In contrast, the
mutated TGF-13 gene used in the present study can achieve direct
secretion of active TGF-131 into the extracellular space. This
should allow for higher TGF-/3 activity within the glomerular
microenvironment. Since lower concentrations of active TGF-p
might promote whereas higher concentrations inhibit mesangial
cell proliferation [44], differences in local TGF-p bioactivity could
be the basis of different outcomes.
The proinflammatory cytokine IL-i is known to have a central
role in various inflammatosy processes [45]. In the kidney, IL-i is
involved in several types of glomerular disease [33, 461, and
therapeutic intervention with IL-i receptor antagonist is feasible
[47, 48]. IL-i stimulates proliferation and production of inflam-
matory mediators such as cytokines, chemokines, neutral protein-
ases, bioactive lipids, and reactive oxygen/nitrogen species by
mesangial cells [33, 49, 50]. These molecules subsequently induce
enhanced cell proliferation, leukocyte influx, and destruction of
glomerular structure, leading to progression of the inflammatory
process. TGF-p may have several actions which counteract these
IL-i effects [7—9, 32, 45, Si]. Using the MMP-9 as an indicator, we
showed that mesangial cells and glomeruli expressing active
TGF-pl exhibited reduced responsiveness to IL-if3. This finding
implies that, in some particular pathological situations, TGF-f3
could act as a protective mediator in the glomerulus by opposing
the actions of IL-i. Recently, Nakagawa and colleagues provided
preliminary evidence that administration of decorin, a natural
inhibitor of TGF-f3, into rats subjected to anti-glomerular base-
ment membrane nephritis induced deterioration of disease, that
is, enhanced glomerular cellularity, accelerated crescent forma-
tion, and increased proteinuria [521. In this experimental model,
IL-i plays a pivotal role in the generation of glomerular injury and
proteinuria [47, 48]. If TGF-f3 has an opposing effect on IL-i
action within the glomerulus, an anti-inflammatory potential of
TGF-p in this nephritis model is raised.
The mechanism involved in the antagonism by TGF-13 to IL-i is
not well understood. As has been reported in chondrocytes and
Iymphoid/myeloid progenitor cells, down-regulation of IL-i re-
ceptor expression might be a possible mechanism [7, 32]. How-
ever, the fact that induction of monocyte chemoattractant pro-
tein-I (MCP-i) by IL-1j3 is not inhibited by TGF-/31 in mesangial
cells (M. Kitamura, unpublished observation), seems to exclude
this possibility. We have recently found that induction of MMP-9
by IL-1f3 is mediated by dual regulation of activator protein-i
(AP-i) and nuclear factor-KB (NF-B) in mesangial cells [27].
TGF-f3 might exert its inhibitory effect by selectively interfering
with the activation pathways of these transacting molecules in the
intracellular signaling cascade. Further investigation will be re-
quired to address the mechanism and spectrum of counteractions
by TGF-13 against the proinflammatoty cytokines in glomerular
cells.
The biological potency of TGF-f3 on glomerular matrix metab-
olism is complicated. In general, TGF-f3 down-regulates expres-
sion of matrix-degrading proteinases and up-regulates proteinase
inhibitors, thereby inhibiting matrix degradation by tissue cells [1].
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In this study, we found that IL-I induction of MMP-9 in glomer-
ular cells was suppressed by TGF-p1. The reduced MMP-9
activity was closely correlated with the repressed mRNA expres-
sion, implying the involvement of transcriptional suppression. On
the other hand, we also found that MMP-2 activity in mesangial
cells was significantly up-regulated by transfection with a TGF-/31
gene or externally added TGF-f31. This was due to the transcrip-
tional activation since both TGF-13 transfectants expressed higher
levels of MMP-2 mRNA compared to mock transfected cells (M.
Kitamura, unpublished data). These findings are in agreement
with a recent report by Marti and colleagues [53]. Although the
pathophysiological relevance of this observation is not clear, the
negative contribution of TGF-13 to degradation of glomerular
matrix may not be as simple as has been proposed, and further
study is required to clarify this issue.
In the inflammation of vital organs, TGF-p is regarded as a
candidate which induces fibrogenesis [54]. In contrast, this mole-
cule also exerts multipotent and powerful suppressive action on
the cells involved in cellular and/or humoral immune responses
[51 This evidence, together with reports showing that TGF-/31 is
constitutively expressed in the normal glomeruli [14, 56, 57],
implies that this ubiquitous molecule may participate in the
prevention or recovery of the glomerulus from inflammation.
Indeed, Shull and co-workers have shown that targeted disruption
of the TGF-/31 gene induced multifocal inflammatory disorders in
murine organs [58] including the kidney. The anti-inflammatory
activity of TGF-/3 has been harnessed for the treatment of
experimental autoimmune/inflammatory disorders such as arthri-
tis, encephalomyelitis, or insulitis [59—611. If its local production
and activation are tightly controlled, TGF-/3 could have a benefi-
cial effect in the early stages of glomerular inflammation.
In summary, we have demonstrated the anti-mitogenic and
anti-IL-i effects of TGF-pi on the glomerulus. This study also
demonstrates the feasibility of a gene transfer approach which
enables the glomerulus to produce biologically active molecules in
vivo. Using this system, it would be possible to exert control over
the activity of certain pathogenic mediators or specific cell types
within the glomerular microenvironment.
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